Cancer

Quibim Announces New Board of Directors To Promote Growth And Strategic Expansion

NEW YORK & VALENCIA, Spain & CAMBRIDGE, England--(BUSINESS WIRE)--#AIinHealthcare--Quibim, the global pioneer in imaging biomarkers for precision medicine, is pleased…

9 months ago

More than Half of the “Sandwich Generation” are at High Risk of Burnout with 64% of them Screening Positive for Depression and Anxiety – Cleo 2nd Annual Family Health Index

New Findings from 12,500 Assessments Completed by Working Caregivers Reveal that Critical Health Needs Go Largely Unaddressed by Employers and…

9 months ago

New Analytical Validation Confirms Accuracy and Precision of MyProstateScore 2.0

Study finds MPS2 scores are highly reproducible across DRE and non-DRE urine samples alike. ANN ARBOR, Mich., April 7, 2025…

9 months ago

Belong.Life’s Advanced AI Technology Selected to Power New Menopause Support Solution

'Ask Elina' Harnesses Belong's Data and Expertise in Conversational AI to Help Women Navigate Menopause, Manage Symptoms and Explore Options NEW…

9 months ago

DOSIsoft PLANET® Onco Dose receives CE MDR Mark and new FDA 510(k) clearance

PARIS, April 7, 2025 /PRNewswire/ -- DOSIsoft, leading provider of patient-specific imaging and dosimetry software solutions for radiation oncology and nuclear…

9 months ago

European Commission approves subcutaneous RYBREVANT®▼ (amivantamab) for the treatment of patients with advanced EGFR-mutated non-small cell lung cancer

Subcutaneous (SC) amivantamab offers patients greater convenience, reducing administration time from hours to minutes and with a five-fold reduction in…

9 months ago

Senti Bio Joins Webull Corporate Connect Service Platform

Company advancing off-the-shelf CAR-NK cell therapy programs for oncology indications with lead candidate, SENTI-202, in clinical development for the treatment…

9 months ago

Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma

Designations Follow Recent Investigational New Drug (IND) Application Clearance for the RESOLUTION Basket Study of ALLO-329 in RheumatologyDual CD19/CD70 CAR…

9 months ago

Aspargo Labs Expands Global Leadership Team

NEW YORK, April 07, 2025 (GLOBE NEWSWIRE) -- Aspargo Labs, Inc. ("Aspargo Labs" or the "Company"), a specialty pharmaceutical and…

9 months ago